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Introduction {#cam41244-sec-0001}
============

Page and Anderson first described PLC in 1987 [1](#cam41244-bib-0001){ref-type="ref"}, Eusebi et al. [2](#cam41244-bib-0002){ref-type="ref"} and Weidener [3](#cam41244-bib-0003){ref-type="ref"} consolidated the histological features. PLC is a rare form of invasive lobular carcinoma (ILC) with important clinical values [4](#cam41244-bib-0004){ref-type="ref"}. PLC has the specific loosely cohesive growth pattern of ILC and shares molecular alterations with ILC, such as the alterations of gene CDH1 [5](#cam41244-bib-0005){ref-type="ref"}, however, compared with ILC, PLC has its own unique characteristics such as more frequent mitotic figures, increased hyperchromatic, and a single prominent nucleolus etc. [5](#cam41244-bib-0005){ref-type="ref"}. PLC has been shown to be more commonly represented in BRCA2 carriers [6](#cam41244-bib-0006){ref-type="ref"}.

IDC is a group of malignant epithelial tumors that tend to invade adjacent tissues and metastasize to distant sites [7](#cam41244-bib-0007){ref-type="ref"}. Nuclear atypia and pleomorphism of IDC are consistent with PLC [8](#cam41244-bib-0008){ref-type="ref"}. The biological aggression of PLC is related to the genetic alterations of high‐grade ductal carcinoma, such as overexpression of c‐myc and HER2/neu5. Monhollen and Middleton [9](#cam41244-bib-0009){ref-type="ref"}, [10](#cam41244-bib-0010){ref-type="ref"} suggested that PLC carried a higher risk of metastasis and recurrence than IDC. They also demonstrated that PLC had been associated with older age and postmenopausal status. Jung et al. [11](#cam41244-bib-0011){ref-type="ref"} and Jung et al. [12](#cam41244-bib-0012){ref-type="ref"} elucidated that PLC patients tend to be older, to have larger tumor, and to exhibit more axillary LN involvement (higher T and N stages) compared to IDC patients.

Because the incidence of PLC is low, most of the available studies are small retrospective studies or case reports. For this reason, we aim to compare survival outcomes of PLCs with IDCs with large amount of cases and identify prognostic factors that lead to survival differences between the histologic subtypes of breast cancer using the Surveillance, Epidemiology, and End Result (SEER) database. We find 131 available PLC cases, so the statistical result we get will be more accurate.

Materials and Methods {#cam41244-sec-0002}
=====================

Patient selection and data acquisition {#cam41244-sec-0003}
--------------------------------------

The SEER data we use was released in April 2016, which includes data from 18 population‐based registries. The data covers the period from 1973 to 2013. The data of tumor grade, location, and histology are recorded according to the International Classification of Diseases for Oncology Version 3 (ICD‐O‐3). The patient\'s inclusion criteria were as follows: patients age older than 15, breast cancer (ICD‐O‐3 site code C50), unilateral breast cancer as the first and only cancer diagnosis, diagnosis not obtained from autopsy or a death certificate, there was only one major site, pathologically confirmed invasive ductal carcinoma no other specified (ICD‐O‐3 8500/3) (IDC‐NOS) and pleomorphic lobular carcinoma (ICD‐O‐3 8022/3) with invasion (behavior code ICD‐O‐3 malignant), time of diagnosis from 1990 to 2009.

The items of demographic characteristics included age at diagnosis, the year of diagnosis, marital status, race, laterality, AJCC stage, tumor size, histologic grade, regional LN state, ER status, and PR status. We treated the age of diagnosis as a binary variable that uses the following age group classification: 15--49 years old and 50--85+ years old. We classified year of diagnosis as 1990--1999, 2000--2009.

Statistical analysis {#cam41244-sec-0004}
--------------------

The clinical and pathological features are compared using Pearson\'s chi‐square test or Fisher\'s exact test for classification of nominal data and Cochran--Mantel--Haenszel (CMH) chi‐square test for classification of nominal data. The Kaplan--Meier method is performed to generate 5‐year disease‐specific survival curves, and log‐rank test is performed to compare the difference between curves. In order to eliminate the influencing factors other than the disease type between the two group and get more accurate results, we match every PLCs to IDCs based on the following factors: race, age, year of diagnosis, laterality, PR status, tumor grade, marital status, LN status, tumor stage, ER status, surgery type and radiation. We use propensity score matching method in SPSS and to test match quality to determine the matching balance. All analyzes are performed with the SPSS statistical software, 24.0 version (Armonk, NY, IBM Crop). A two‐sided *P *\<* *0.05 is considered to indicate statistical significance.

Results {#cam41244-sec-0005}
=======

Clinicopathological features of PLC and IDC {#cam41244-sec-0006}
-------------------------------------------

According to the criteria we set, we selected 460,240 patients with breast cancer, including 131 PLC patients and 460,109 IDC patients. The tumor demographics and treatment characteristics of histological subtypes are summarized in Table [1](#cam41244-tbl-0001){ref-type="table-wrap"}. Tumor characteristics with significant statistical differences included histological grade, AJCC stage, and LN status. PLC patients presented with higher grade (grade III: 43.6% vs. 37.3%; *P *\<* *0.01) and higher AJCC stage than IDC patients (stage III: 19.1% vs. 11.8% and stage IV: 3.80% vs. 3.40%, respectively; *P *\<* *0.01). The PLC patients have more LN‐positive than IDC patients (LN positive: 42.7% vs. 29.9% *P *\<* *0.01) and lower median survival months (PLC 84 ± 51.03 vs. IDC 105.2 ± 64.39 *P *\<* *0.01) than IDC patients. In the Black race and unmarried population, the proportion of PLC patients was higher than in IDC patients (16.0% vs. 9.1% *P *=* *0.018; 14.5% vs. 12.3% *P *=* *0.023, respectively). The two groups were treated differently. Mastectomy rate was higher in PLCs than in IDCs (54.2% vs. 30.4%; *P *\<* *0.01). PLC patients prefer to be less likely to receive radiation therapy than IDC (57.3% vs. 50.9% *P *=* *0.048). We did not find significant difference in laterality, ER, and PR.

###### 

Patient characteristics in PLC compared to IDC.[a](#cam41244-note-0004){ref-type="fn"}

  Variables                                          IDC, *n* = 460,109 (%)   PLC, *n* = 131 (%)   Total, *n* = 460,240 (%)   *P* [b](#cam41244-note-0005){ref-type="fn"}   
  -------------------------------------------------- ------------------------ -------------------- -------------------------- --------------------------------------------- ------------
  Median survival months                             105.2 ± 64.39            84 ± 51.03           105.01 ± 64.39             **\<0.01**                                    
  Year of diagnosis                                  1990--1999               153,948 (33.5)       13 (9.9)                   153,961 (33.5)                                **\<0.01**
  2000--2009                                         306,161 (66.5)           118 (90.1)           306,279 (66.5)                                                           
  Age at diagnosis                                   15--49                   112,714 (24.5)       28 (21.4)                  112,742 (24.5)                                0.466
  50--85+                                            347,395 (75.5)           103 (78.6)           347,498 (75.5)                                                           
  Race                                               Black                    41,804 (9.1)         21 (16.0)                  41,825 (9.1)                                  **0.018**
  White                                              379,964 (82.6)           98 (74.8)            380,062 (82.6)                                                           
  Others[c](#cam41244-note-0006){ref-type="fn"}      38,341 (8.3)             12 (9.2)             38,353 (8.3)                                                             
  Marital status                                     Married                  387,230 (84.2)       102 (77.9)                 387,332 (84.2)                                **0.023**
  Unmarried[d](#cam41244-note-0007){ref-type="fn"}   56,805 (12.3)            19 (14.5)            56,824 (12.3)                                                            
  Unknown                                            16,074 (3.5)             10 (7.6)             16,084 (3.5)                                                             
  Laterality                                         Left                     233,561 (50.8)       62 (47.3)                  233,623 (50.8)                                0.485
  Right                                              226,548 (49.2)           69 (52.7)            226,617 (49.2)                                                           
  Grade                                              I                        75,619 (16.4)        1 (0.8)                    75,620 (16.4)                                 **\<0.01**
  II                                                 176,421 (38.3)           41 (31.3)            176,462 (38.3)                                                           
  III                                                166,700 (37.3)           57 (43.6)            166,757 (37.3)                                                           
  Unknown                                            36,369 (7.9)             32 (24.4)            36,401 (7.9)                                                             
  AJCC stage                                         0                        21 (0.0)             0 (0.0)                    21 (0.0)                                      **\<0.01**
  I                                                  213,644 (46.4)           34 (26)              213,678 (46.4)                                                           
  II                                                 145,408 (31.6)           59 (45.0)            145,467 (31.6)                                                           
  III                                                54,398 (11.8)            25 (19.1)            54,423 (11.8)                                                            
  IV                                                 15,827 (3.4)             5 (3.8)              15,832 (3.4)                                                             
  Unknown                                            30,811 (6.7)             8 (6.1)              30,819 (6.7)                                                             
  LN status                                          Negative                 257,886 (56.0)       59 (45)                    257,945 (56)                                  **\<0.01**
  Positive                                           137,444 (29.9)           56 (42.7)            137,500 (29.9)                                                           
  Unknown                                            64,779 (14.1)            16 (12.2)            64,795 (14.1)                                                            
  ER status                                          Negative                 97,679 (21.2)        34 (26)                    97,713 (21.2)                                 0.351
  Positive                                           303,405 (65.9)           79 (60.3)            303,484 (65.9)                                                           
  Unknown                                            59,025 (12.8)            18 (13.7)            59,043 (12.8)                                                            
  PR status                                          Negative                 137,281 (29.8)       43 (32.8)                  137,324 (29.8)                                0.748
  Positive                                           255,245 (55.5)           69 (52.7)            255,314 (55.5)                                                           
  Unknown                                            67,583 (14.7)            19 (14.5)            67,602 (14.7)                                                            
  Surgery type                                       Mastectomy               139,769 (30.4)       71 (54.2)                  139,840 (30.4)                                **\<0.01**
  Lumpectomy                                         185,118 (40.2)           46 (35.1)            185,164 (40.2)                                                           
  No surgery                                         16,730 (3.6)             5 (3.8)              16,735 (3.6)                                                             
  Unknown                                            118,492 (25.8)           9 (6.9)              118,510 (25.8)                                                           
  Radiation                                          Yes                      212,702 (46.2)       49 (37.4)                  212,751 (46.2)                                **0.048**
  No                                                 234,239 (50.9)           75 (57.3)            234,314 (50.9)                                                           
  Unknown                                            13,168 (2.9)             7 (5.3)              13,175 (2.9)                                                             

AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PLC, Pleomorphic lobular breast carcinoma; IDC, infiltrating ductal carcinoma; LN, lymph node; PR, progesterone receptor.

The data are presented as the No. (percentage) of patients unless otherwise indicated.

*P*‐value of the Chi‐square test to compare the PLC and IDC groups. The value of bold is statistically significant.

Including American Indian/Alaskan native, Asian/Pacific Islander, and others‐unspecified.

Including divorced, separated, single (never married), and widowed.

John Wiley & Sons, Ltd

Comparison of survival outcome between PLCs and IDCs {#cam41244-sec-0007}
----------------------------------------------------

We use Kaplan--Meier plots to evaluate DSS and OS of these two histologic subtypes (Fig. [1](#cam41244-fig-0001){ref-type="fig"}A and B). IDCs have better DSS and OS than the overall PLC population (*χ* ^2^ = 7.937, *P *=* *0.0078; *χ* ^2^ = 6.619, *P *=* *0.0036). Five‐year DSS rate of IDC and PLC were 89.0% and 84.7%, respectively. Five‐year OS rate of IDC and PLC were 80.3% and 73.5%, respectively. We used a Cox proportional hazards model to study the effects of baseline characteristics on DSS with univariate and multivariate analysis (Table [2](#cam41244-tbl-0002){ref-type="table-wrap"}). In the univariate analysis, the prognostic indicators were significantly associated with DSS including patients diagnosed after 2000, patients diagnosed after the age of 50, Black race, higher grade, higher AJCC stage, LN positive, ER/PR negative, no surgery, and radiation. These variables were included in multivariate analysis. The results of multivariate analysis confirmed the prognostic factors of univariate analysis. However, after adjusting for other prognostic factors, the histological type was no longer an independent prognostic factor in multivariate analysis (*P *=* *0.120).

![The disease‐specific survival and disease‐overall survival of the two groups. Kaplan--Meier test for disease‐specific survival (*χ* ^2^ = 7.937, *P *=* *0.0078, Fig. [1](#cam41244-fig-0001){ref-type="fig"}A) and disease‐overall survival (*χ* ^2^ = 6.619, *P *=* *0.0036, Fig. [1](#cam41244-fig-0001){ref-type="fig"}B) to compare PLC patients and IDC patients.](CAM4-6-2867-g001){#cam41244-fig-0001}

###### 

Univariate and multivariate analysis of disease‐specific survival (DSS)

  Variables                                          Univariate analysis           Multivariate analysis                                           
  -------------------------------------------------- ----------------------------- ----------------------- -------------------------- ------------ --------
  Year of diagnosis                                  1990--1999                    Reference               --                         Reference    --
  2000--2009                                         0.840 (0.831--0.848)          **\<0.01**              0.923 (0.907--0.938)       **\<0.01**   
  Age at diagnosis                                   15--49                        Reference               **--**                     Reference    --
  50--85+                                            2.120 (2.092--2.147)          **\<0.01**              2.330 (2.299--2.361)       **\<0.01**   
  Race                                               White                         Reference               **--**                     Reference    **--**
  Black                                              1.398 (1.377**--**1.419)      **\<0.01**              1.244 (1.225**--**1.263)   **\<0.01**   
  Other[a](#cam41244-note-0009){ref-type="fn"}       0.694 (0.680**--**0.708)      **\<0.01**              0.729 (0.715**--**0.744)   **\<0.01**   
  Marital status                                     Married                       Reference               **--**                     Reference    **--**
  Unmarried[b](#cam41244-note-0010){ref-type="fn"}   1.010 (0.996**--**1.025)      0.159                   1.014 (0.999**--**1.029)   0.066        
  Laterality                                         Left                          Reference               **--**                     Reference    **--**
  Right                                              0.991 (0.982**--**1.001)      0.068                   1.000 (0.991**--**1.009)   0.965        
  Histologic type                                    PLC                           Reference               **--**                     Reference    **--**
  IDC                                                0.691 (0.534**--**0.893)      **\<0.01**              0.815 (0.630**--**1.055)   0.120        
  Grade                                              I                             Reference               **--**                     Reference    **--**
  II                                                 1.2947 (1.274**--**1.315)     **\<0.01**              1.154 (1.136**--**1.172)   **\<0.01**   
  III                                                1.667 (1.642**--**1.693)      **\<0.01**              1.365 (1.342**--**1.387)   **\<0.01**   
  AJCC stage                                         I                             Reference               **--**                     Reference    **--**
  II                                                 1.350 (1.334**--**1.366)      **\<0.01**              1.604 (1.553**--**1.656)   **\<0.01**   
  III                                                2.699 (2.662**--**2.736)      **\<0.01**              2.423 (2.327**--**2.523)   **\<0.01**   
  IV                                                 10.760 (10.561**--**10.963)   **\<0.01**              4.469 (4.331**--**4.613)   **\<0.01**   
  LN status                                          Negative                      Reference               **--**                     Reference    **--**
  Positive                                           1.833 (1.813**--**1.853)      **\<0.01**              1.188 (1.170**--**1.206)   **\<0.01**   
  ER status                                          Negative                      Reference               **--**                     Reference    **--**
  Positive                                           0.804 (0.795**--**0.813)      **\<0.01**              0.944 (0.930**--**0.959)   **\<0.01**   
  PR status                                          Negative                      Reference               **--**                     Reference    **--**
  Positive                                           0.758 (0.750**--**0.767)      **\<0.01**              0.868 (0.855**--**0.880)   **\<0.01**   
  Surgery type                                       No surgery                    Reference               **--**                     Reference    **--**
  Lumpectomy                                         0.145 (0.142**--**0.148)      **\<0.01**              0.604 (0.590**--**0.619)   **\<0.01**   
  Mastectomy                                         0.226 (0.221**--**0.230)      **\<0.01**              0.690 (0.674**--**0.706)   **\<0.01**   
  Radiation                                          No                            Reference               **--**                     Reference    **--**
  Yes                                                0.590 (0.584**--**0.595)      **\<0.01**              0.688 (0.681**--**0.695)   **\<0.01**   

Multivariate analysis included year of diagnosis, age at diagnosis, race, marital status, laterality, grade, histology, LN status, ER/PR status, surgery type and radiation. HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PLC, Pleomorphic lobular breast carcinoma; IDC, infiltrating ductal carcinoma; LN, lymph node; PR, progesterone receptor. The bold number of p‐value is statistically significant

Including American Indian, Alaska Native, Asian, Pacific Islander and others**--**unspecified.

Including divorced, separated, single (never married), and widowed.

John Wiley & Sons, Ltd

The survival analysis of the matched group {#cam41244-sec-0008}
------------------------------------------

In order to ensure that the difference in survival results is not based on the histological subgroup of demographic and clinical characteristics of the baseline differences, we use the propensity score matching method to perform a 1:1 (IDC: PLC) matched case--control analysis. We obtained 234 patients, of which 117 cases were of PLC, and the remaining117 cases of IDC (Table [3](#cam41244-tbl-0003){ref-type="table-wrap"}). We used the Cox proportional hazards model for univariate and multivariate analysis to study the effect of baseline characteristics on DSS (Table [4](#cam41244-tbl-0004){ref-type="table-wrap"}). For matched groups, we find that there is no statistically significant difference in DSS and OS between PLCs and IDCs (Fig. [2](#cam41244-fig-0002){ref-type="fig"}A *χ* ^2^ = 0.2525, *P *=* *0.6153, Fig. [2](#cam41244-fig-0002){ref-type="fig"}B *χ* ^2^ = 0.2219, *P *=* *0.6376).

###### 

Patient characteristics in matched groups

  Variables                                          IDC          PLC          Total        *P* **--**value[b](#cam41244-note-0013){ref-type="fn"}   
  -------------------------------------------------- ------------ ------------ ------------ -------------------------------------------------------- -------
  Year of diagnosis                                  1990--1999   9 (7.7)      9 (7.7)      18 (7.7)                                                 1.000
  2000--2009                                         108 (92.3)   108 (92.3)   216 (92.3)                                                            
  Age at diagnosis                                   15--49       21 (17.9)    21 (17.9)    42 (17.9)                                                1.000
  50--86+                                            96 (82.1)    96 (82.1)    192 (82.1)                                                            
  Race                                               White        91 (77.8)    91 (77.8)    182 (77.8)                                               1.000
  Black                                              15 (12.8)    15 (12.8)    30 (12.8)                                                             
  Other[c](#cam41244-note-0014){ref-type="fn"}       11 (9.4)     11 (9.4)     22 (9.4)                                                              
  Marital status                                     Married      100 (85.5)   100 (85.5)   200 (85.5)                                               1.000
  Unmarried[d](#cam41244-note-0015){ref-type="fn"}   10 (8.5)     10 (8.5)     10 (8.5)                                                              
  Unknown                                            7 (6)        7 (6)        14 (6)                                                                
  Laterality                                         Right        61 (52.1)    61 (52.1)    122 (52.1)                                               1.000
  Left                                               56 (47.9)    56 (47.9)    112 (47.9)                                                            
  Grade                                              I            1 (0.9)      1 (0.9)      2 (0.9)                                                  1.000
  II                                                 37 (31.6)    37 (31.6)    74 (31.6)                                                             
  III                                                53 (45.3)    53 (45.3)    106 (45.3)                                                            
  Unknown                                            26 (22.2)    22 (22.2)    44 (22.2)                                                             
  AJCC stage                                         I            34 (29.1)    34 (29.1)    68 (29.1)                                                1.000
  II                                                 53 (45.3)    53 (45.3)    106 (45.3)                                                            
  III                                                21 (17.9)    21 (17.9)    42 (17.9)                                                             
  IV                                                 3 (2.6)      3 (2.6)      6 (2.6)                                                               
  II                                                 6 (5.1)      6 (5.1)      12 (45.1)                                                             
  LN status                                          III          49 (41.9)    49 (41.9)    98 (41.9)                                                1.000
  Negative                                           57 (48.7)    57 (48.7)    114 (48.7)                                                            
  Unknown                                            11 (9.4)     11 (9.4)     22 (9.4)                                                              
  ER status                                          Positive     74 (63.2)    74 (63.2)    148 (63.2)                                               1.000
  Negative                                           30 (25.6)    30 (25.6)    60 (25.6)                                                             
  Unknown                                            13 (11.1)    13 (11.1)    26 (11.1)                                                             
  PR status                                          Positive     63 (53.8)    63 (53.8)    126 (53.8)                                               1.000
  Negative                                           40 (34.2)    40 (4.2)     80 (34.2)                                                             
  Unknown                                            14 (12)      14 (12)      28 (12)                                                               
  Surgery type                                       Mastectomy   67 (57.3)    67 (57.3)    134 (57.3)                                               1.000
  Lumpectomy                                         40 (34.2)    40 (34.2)    80 (34.2)                                                             
  No surgery                                         4 (3.4)      4 (3.4)      8 (3.4)                                                               
  Unknown                                            6 (5.1)      6 (5.1)      12 (5.1)                                                              
  Radiation                                          Yes          111 (94.9)   111 (94.9)   122 (94.9)                                               1.000
  No                                                 6 (5.1)      6 (5.1)      12 (5.1)                                                              

AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PLC, Pleomorphic lobular breast carcinoma; IDC, infiltrating ductal carcinoma; LN, lymph node, PR, progesterone receptor.

The data are presented as the No. (percentage) of patients unless otherwise indicated.

*P*‐value of the Chi‐square test to compare the PLC and IDC groups.

Including American Indian/Alaskan native, Asian/Pacific Islander and others‐unspecified.

Including divorced, separated, single (never married) and widowed.

John Wiley & Sons, Ltd

###### 

Univariate and multivariate analysis of disease‐specific survival (DSS) in matched groups

  **Variables**                                      Univariate analysis     Multivariate analysis                                        
  -------------------------------------------------- ----------------------- ----------------------- ----------------------- ------------ ----
  Year of diagnosis                                  1990--1999              Reference               --                      Reference    --
  2000--2009                                         0.796 (0.419--1.512)    0.485                   0.963 (0.205--4.516)    0.962        
  Age at diagnosis                                   15--49                  Reference               --                      Reference    --
  50--85+                                            3.756 (1.641--8.596)    **\<0.01**              4.455 (1.751--11.338)   **\<0.01**   
  Race                                               White                   Reference               --                      Reference    --
  Black                                              1.738 (0.994--3.039)    0.053                   1.723 (0.832--3.571)    0.143        
  Other[a](#cam41244-note-0017){ref-type="fn"}       1.082 (0.540--2.168)    0.823                   1.830 (0.843--3.973)    0.127        
  Marital status                                     Married                 Reference               --                      Reference    --
  Unmarried[b](#cam41244-note-0018){ref-type="fn"}   2.167 (1.176--3.994)    0.013                   1.011 (0.424--2.411)    0.980        
  Laterality                                         Left                    Reference               --                      Reference    --
  Right                                              1.056 (0.705--1.583)    0.790                   0.685 (0.404--1.161)    0.160        
  Group                                              PLC                     Reference               --                      Reference    --
  IDC                                                1.078 (0.720--1.614)    0.715                   0.946 (0.617--1.450)    0.798        
  Grade                                              I                       Reference               --                      Reference    --
  II                                                 2.695 (2.602--2.791)    **\<0.01**              1.839 (1.775--1.905)    **\<0.01**   
  III                                                5.641 (5.453--5.835)    **\<0.01**              2.722 (2.628--2.820)    **\<0.01**   
  AJCC stage                                         I                       Reference               --                      Reference    --
  II                                                 1.361 (0.792--2.340)    0.265                   2.0701.004--4.268)      **0.049**    
  III                                                2.415 (1.325--4.402)    **\<0.01**              4.519 (2.001--10.207)   **\<0.01**   
  IV                                                 11.49 (4.531--29.149)   **\<0.01**              9.840 (2.699--35.868)   **\<0.01**   
  LN status                                          Negative                Reference               --                      Reference    --
  Positive                                           1.287 (0.828--2.001)    0.263                   3.512 (1.443--8.549)    **\<0.01**   
  ER status                                          Positive                Reference               --                      Reference    --
  Negative                                           2.127 (1.350--3.351)    **\<0.01**              1.665 (0.466--5.952)    0.433        
  PR status                                          Positive                Reference               --                      Reference    --
  Negative                                           2.276 (1.457--3.556)    **\<0.01**              0.903 (0.436--1.867)    0.782        
  Surgery type                                       No surgery              Reference               --                      Reference    --
  Lumpectomy                                         0.131 (0.056--031)      **\<0.01**              0.468 (0.117--1.883)    0.285        
  Mastectomy                                         0.222 (0.100--0.490)    **\<0.01**              0.676 (0.182--2.505)    0.557        
  Radiation                                          Yes                     Reference               --                      Reference    --
  No                                                 1.375 (0.636--2.973)    0.418                   2.720 (01.084--6.826)   **0.033**    

Multivariate analysis included year of diagnosis, age at diagnosis, race, marital status, laterality, grade, histology, LN status, ER/PR status, surgery type, and radiation. HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PLC, Pleomorphic lobular breast carcinoma; IDC, infiltrating ductal carcinoma; LN, lymph node; PR, progesterone receptor. The value of bold is statistically significant.

Including American Indian, Alaska Native, Asian, Pacific Islander and others‐unspecified.

Including divorced, separated, single (never married) and widowed.

John Wiley & Sons, Ltd

![The disease‐specific survival and disease‐overall survival of 1:1 matched groups of PLC patients and IDC patients. Kaplan--Meier test for disease‐specific survival (*χ* ^2^ = 0.2525, *P *=* *0.06153, Fig. [2](#cam41244-fig-0002){ref-type="fig"}A) and disease‐overall survival. (*χ* ^2^ = 0.2219, *P *=* *0.6376, Fig. [2](#cam41244-fig-0002){ref-type="fig"}B) to compare 1:1 matched groups of PLC patients and IDC patients.](CAM4-6-2867-g002){#cam41244-fig-0002}

The baseline and survival outcomes of ER‐positive subgroups {#cam41244-sec-0009}
-----------------------------------------------------------

The proportion of patients with ER positive in PLC and IDC is high and we observed some results in these patients. (Table [5](#cam41244-tbl-0005){ref-type="table-wrap"}). ER‐positive PLC patients had higher tumor grade, higher AJCC stage, and shorter median survival months than ER‐positive IDC patients. However, there was no statistically significant difference in LN status between ER‐positive PLC patients and ER‐positive IDC patients. Compared with the two groups of ER‐positive patients, there was no statistically significant difference in DSS and OS curves (Fig. [3](#cam41244-fig-0003){ref-type="fig"}A *P *=* *0.1521; Fig. [3](#cam41244-fig-0003){ref-type="fig"}B, *P *=* *0.3675).

###### 

ER‐positive patient characteristics in PLC compared to IDC[a](#cam41244-note-0020){ref-type="fn"}

  Variables                                          IDC *n* = 303,405(%)   PLC *n* = 79(%)   Total *n* = 303,484(%)   *P*‐value[b](#cam41244-note-0021){ref-type="fn"}   
  -------------------------------------------------- ---------------------- ----------------- ------------------------ -------------------------------------------------- ------------
  Median survival months                             105.7 ± 61.154         86.71 ± 44.525    **\<0.01**                                                                  
  Year of diagnosis                                  1990--1999             93,315 (30.8)     4 (5.1)                  93,319 (30.7)                                      **\<0.01**
  2000--2009                                         210,090 (69.2)         75 (94.9)         210,165 (69.3)                                                              
  Age at diagnosis                                   15--49                 67,108 (22.1)     14 (17.7)                67,122 (22.1)                                      0.420
  50--85+                                            236,297 (77.9)         65 (82.3)         236,362 (77.9)                                                              
  Race                                               Black                  21,190 (7.0)      9 (11.4)                 21,199 (7.0)                                       0.254
  White                                              256,106 (84.4)         62 (78.5)         256,188 (84.4)                                                              
  Other[c](#cam41244-note-0022){ref-type="fn"}       26,109 (8.6)           8 (10.1)          26,117 (8.6)                                                                
  Marital status                                     Married                257,816 (85.0)    66 (83.5)                257,882 (85.0)                                     0.055
  Unmarried[d](#cam41244-note-0023){ref-type="fn"}   36,195 (11.9)          7 (8.9)           36,202 (11.9)                                                               
  Laterality                                         Left                   153,103 (50.5)    38 (48.1)                153,141 (50.5)                                     0.759
  Right                                              150,302 (49.5)         41 (51.9)         150,343 (49.5)                                                              
  Grade                                              I                      64,652 (21.3)     1 (1.3)                  64,653 (21.3)                                      **\<0.01**
  II                                                 138,298 (45.6)         35 (44.3)         138,333 (45.6)                                                              
  III                                                82,044 (27)            24 (30.3)         78,280 (27)                                                                 
  Unknown                                            18,411 (6.1)           19 (24.1)         18,430 (6.1)                                                                
  AJCC stage                                         I                      153,897 (50.7)    26 (32.9)                153,923 (50.7)                                     **\<0.01**
  II                                                 93,087 (30.7)          28 (35.4)         93,115 (30.7)                                                               
  III                                                31,848 (10.5)          18 (22.8)         31,866 (10.5)                                                               
  IV                                                 9028 (3.0)             3 (3.8)           9031 (3.0)                                                                  
  Unknown                                            15,531 (5.1)           4 (5.1)           15,535 (5.1)                                                                
  LN status                                          Negative               175,444 (57.8)    37 (46.8)                175,481 (57.8)                                     0.059
  Positive                                           89,877 (29.6)          33 (41.8)         89,910 (29.6)                                                               
  Unknown                                            38,084 (12.6)          9 (11.4)          38,093 (12.6)                                                               
  PR status                                          Negative               48,553 (16.0)     12 (15.2)                48,565 (16.0)                                      0.996
  Positive                                           246,280 (81.2)         65 (82.3)         246,345 (81.2)                                                              
  Unknown                                            8572 (2.8)             2 (2.5)           8574 (2.8)                                                                  
  Surgery type                                       Mastectomy             89,954 (29.6)     44 (55.7)                89,998 (29.7)                                      **\<0.01**
  Lumpectomy                                         134,125 (44.2)         29 (36.7)         134,154 (44.2)                                                              
  No surgery                                         8916 (2.9)             4 (5.1)           8920 (2.9)                                                                  
  Unknown                                            278 (0.1)              0 (0)             278 (0.1)                                                                   
  Radiation                                          No                     145,644 (48.0)    40 (50.6)                145,684 (48.0)                                     **\<0.01**
  Yes                                                149,760 (49.4)         32 (40.5)         149,778 (49.4)                                                              
  Unknown                                            8015 (2.6)             7 (8.9)           8022 (2.6)                                                                  

AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PLC, Pleomorphic lobular breast carcinoma; IDC, infiltrating ductal carcinoma; LN, lymph node; PR, progesterone receptor.

The data are presented as the No. (percentage) of patients unless otherwise indicated.

*P*‐value of the Chi‐square test to compare the PLC and IDC groups. The value of bold is statistically significant.

Including American Indian/Alaskan native, Asian/Pacific Islander and others‐unspecified.

Including divorced, separated, single (never married), and widowed.
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![The disease‐specific survival and disease‐overall survival of ER‐positive groups of PLC patients and IDC patients. Kaplan--Meier test for disease‐specific survival (*χ* ^2^ = 1.929, *P *=* *0.1521, Fig. [3](#cam41244-fig-0003){ref-type="fig"}A) and disease‐overall survival (*χ* ^2^ = 0.741, *P *=* *0.3674, Fig. [3](#cam41244-fig-0003){ref-type="fig"}B) to compare ER‐positive groups of PLC patients and IDC patients.](CAM4-6-2867-g003){#cam41244-fig-0003}

Discussion {#cam41244-sec-0010}
==========

With the increasing incidence of breast cancer, the incidence of PLC may also increase. Therefore, it is necessary to obtain more knowledge about the clinical and biological characteristics of the PLC. The factors that limit the current research on PLC are small sample size and short follow‐up time. Therefore, previous studies lack accurate research conclusions about the clinical behavior, prognosis, and treatment strategy of PLC.

This study is the largest analysis of the sample size of PLC. In this study, we retrospectively observed the clinical and pathological characteristics of PLC based on a large number of people. What we found indicated that PLCs were associated with higher histologic grade, higher AJCC stage than IDCs.

Many studies have concluded that the prognosis of PLCs is worse than that of IDCs [2](#cam41244-bib-0002){ref-type="ref"}, [13](#cam41244-bib-0013){ref-type="ref"}. And our Kaplan--Meier analysis result in DSS and OS show a similar result. However, these findings do not indicate that the PLC itself is an aggressive biological phenotype. Therefore, we adjusted the clinicopathological features and compared DSS and OS with multivariate analysis. The results do not prove that the PLC itself affects the prognosis. Furthermore, after 1:1 matching of PLC with IDC by year of diagnosis, age, race, marital status, tumor grade, laterality, AJCC stage, ER status, surgery type, PR status, LN status and radiation, the PLC displayed almost the same result as IDC in DSS and OS.

Limited information about PLC has been reported in previous studies. Jung and Jung [11](#cam41244-bib-0011){ref-type="ref"}, [12](#cam41244-bib-0012){ref-type="ref"} observed that PLCs tend to be older, have larger tumors, and to exhibit more axillary LN involvement (higher T and N stages) than IDCs. In addition, PLCs often display evidence of lymph vascular invasion and a higher proliferative index [13](#cam41244-bib-0013){ref-type="ref"}. Most evidence point to PLCs having a lobular origin that develops into a more aggressive phenotype [14](#cam41244-bib-0014){ref-type="ref"}, [15](#cam41244-bib-0015){ref-type="ref"}. Studies performed earlier showed ER/PR positivity of 9% to 20% in PLC [13](#cam41244-bib-0013){ref-type="ref"}, [16](#cam41244-bib-0016){ref-type="ref"}. Later publications, however, demonstrate ER/PR positivity of 57% to 96% in PLC [17](#cam41244-bib-0017){ref-type="ref"}, [18](#cam41244-bib-0018){ref-type="ref"}. Monhollen et al. elucidated that PLC carry with it a higher risk of metastasis and recurrence then IDC.

However, our research has several shortcomings inevitably. First, the current SEER database does not contain the records of adjuvant chemotherapy Ki‐67 expression and endocrine therapy, so we cannot get some important prognostic factors. Second, because Her‐2 was documented in the seer database only after 2010, our data which were collected from 1990 to 2009, did not include that factor. Third, we used propensity score matching method to accomplish our match. In the procedure, 117 IDCs matched with random selection of 117 patients from the patient population may be the reason for the bias sampling, reducing the actual effect of this study.

Compared with IDC, we found that PLC has unique clinicopathological characteristics associated with poor prognosis. However, after we adjust the demographic and clinical pathology factors, this disadvantage is weakened. Improving the clinical and biological understanding of PLC may lead to more personalized and customized treatment for breast cancer patients.

Conflicts of Interest {#cam41244-sec-0011}
=====================

The authors declare no conflicts of interest.

[^1]: These authors have contributed equally to this work.
